Accordingly, high BCL-2 relative to low MCL-1 expression was reported to indicate BCL-2 inhibitor sensitivity in multiple myeloma, mantle cell lymphoma and Philadelphia-chromosome positive ALL39–41. This evidence concerns the gene BCL2 and plasma cell myeloma.